Offer widely oversubscribed: 2.5 times the total amount of the capital increase
Strong support from French and international leading shareholders and investors
MedinCell (FR0004065605 – MEDCL), a clinical stage pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas (the “Company”), is today announcing the successful completion of its €29.8 million capital increase via a placement with French and international qualified investors through an accelerated bookbuilding process (the “Offering”).
Bryan, Garnier & Co. Limited1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners.